Category - Markets

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $23 from $16 after the company disclosed plans to reinstate dosing of new patients following the FDA decision to lift the partial...

Stifel initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $70 price target. The stock closed at $43.90 on Sept. 12. “We think UroGen offers investors an opportunity to own a company with a late...

Ladenburg Thalmann launched coverage of Rocket Pharmaceuticals (NASDAQ:RCKT) with a “buy” rating and $30 price target. The stock closed at $23.96 on Sept. 12. Rocket is developing potentially curative first-in-class...

Stifel launched coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “hold” rating and $36 price target, saying the risk/reward for the shares is pretty balanced at current levels. The stock closed at $30.77 on Sept...

Stifel initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a “buy” rating and $30 price target. The stock closed at $18.45 on Sept. 12. “We like the near-term catalyst path for Vanda shares as we believe...

J.P. Morgan launched coverage of ObsEva SA (NASDAQ:OBSV) with an “overweight” rating and a price target of $29 at the end of 2019. The stock closed at $14.40 on Sept. 12. “We view ObsEva as an underappreciated, emerging...

Ladenburg Thalmann initiated coverage of Arch Therapeutics (OTCQB:ARTH) with a “buy” rating and price target of $1.25. The stock closed at 46 cents on Sept. 11. The company is developing a novel hemostat to control skin...

Ladenburg Thalmann launched coverage of Novus Therapeutics (NASDAQ:NVUS) with a “buy” rating and $12 price target. The stock closed at $4.53 on Sept. 10. Novus is developing a novel treatment for otitis media (OM)...

H.C. Wainwright raised its price target for Avid Bioservices (NASDAQ:CDMO) to $11 from $6, saying the company’s business development continues to ramp up and reap rewards. The stock closed at $7.17 on Sept. 10. Avid is...

H.C. Wainwright initiated coverage of Melinta Therapeutics (NASDAQ:MLNT) with a “buy” rating and $14 price target. The stock closed at $4.30 on Sep. 10. Melinta is focused on its four marketed drugs, especially its two...